prochlorperazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2274	58-38-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: prochlorperazine mesylate prochlorperazine capazine chlormeprazine chlorperazine meterazin meterazine proazine prochlorpemazine prochlorperazin prochlorpromazine prochlorperazine maleate prochlorperazine edisylate prochlorperazine dimaleate prochlorperzine	A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612) Molecular weight: 373.94 Formula: C20H24ClN3S CLOGP: 4.58 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 9.72 ALOGS: -4.53 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

prochlorperazine mesylate
prochlorperazine
capazine
chlormeprazine
chlorperazine
meterazin
meterazine
proazine
prochlorpemazine
prochlorperazin
prochlorpromazine
prochlorperazine maleate
prochlorperazine edisylate
prochlorperazine dimaleate
prochlorperzine

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Molecular weight: 373.94
Formula: C20H24ClN3S
CLOGP: 4.58
LIPINSKI: 0
HAC: 3
HDO: 0
TPSA: 9.72
ALOGS: -4.53
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O
50	mg	P
0.10	g	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	15 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	22 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 23, 1956	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	537.17	11.75	611	59725	117838	63310848
Drug ineffective	331.86	11.75	305	60031	1044460	62384226
Disease progression	276.43	11.75	451	59885	122307	63306379
Dehydration	263.42	11.75	537	59799	172817	63255869
Diarrhoea	254.86	11.75	1343	58993	714023	62714663
Nausea	248.54	11.75	1519	58817	852952	62575734
White blood cell count decreased	244.18	11.75	458	59878	138646	63290040
Plasma cell myeloma	220.70	11.75	218	60118	35687	63392999
Vomiting	217.99	11.75	1078	59258	558539	62870147
Contraindicated product administered	191.48	11.75	3	60333	217645	63211041
Platelet count decreased	177.73	11.75	361	59975	115761	63312925
Death	175.51	11.75	762	59574	373619	63055067
Synovitis	162.65	11.75	3	60333	186915	63241771
Arthropathy	160.17	11.75	18	60318	234774	63193912
Fatigue	158.79	11.75	1407	58929	886621	62542065
Systemic lupus erythematosus	156.01	11.75	11	60325	208907	63219779
Neutropenia	143.45	11.75	428	59908	174577	63254109
Malignant neoplasm progression	127.61	11.75	257	60079	81864	63346822
Therapeutic product effect decreased	124.02	11.75	18	60318	193169	63235517
Glossodynia	123.78	11.75	13	60323	178863	63249823
Constipation	120.19	11.75	477	59859	224466	63204220
Asthenia	113.11	11.75	686	59650	382918	63045768
Joint swelling	111.34	11.75	89	60247	327577	63101109
Neutrophil count decreased	106.73	11.75	192	60144	56214	63372472
Pericarditis	100.94	11.75	6	60330	131573	63297113
Toxicity to various agents	98.93	11.75	56	60280	247194	63181492
Decreased appetite	93.92	11.75	479	59857	250573	63178113
Hospice care	93.57	11.75	70	60266	7862	63420824
Neovascularisation	84.12	11.75	34	60302	1111	63427575
Neoplasm progression	82.06	11.75	134	60202	36294	63392392
Drug intolerance	81.79	11.75	104	60232	308557	63120129
Therapeutic product effect incomplete	81.76	11.75	11	60325	125045	63303641
Blood magnesium decreased	80.81	11.75	80	60256	13118	63415568
Gangrene	78.91	11.75	57	60279	6066	63422620
Condition aggravated	78.18	11.75	166	60170	402051	63026635
Arterial occlusive disease	78.01	11.75	56	60280	5902	63422784
Full blood count decreased	77.47	11.75	109	60227	25915	63402771
Akathisia	76.52	11.75	66	60270	9080	63419606
Neuropathy peripheral	75.71	11.75	259	60077	113408	63315278
Infusion related reaction	73.41	11.75	75	60261	245446	63183240
Wound	72.76	11.75	32	60304	163231	63265455
Pleural effusion	72.55	11.75	224	60112	92986	63335700
Abdominal pain	71.79	11.75	501	59835	292955	63135731
Thrombosis	68.50	11.75	174	60162	64581	63364105
Carbohydrate antigen 125 increased	68.18	11.75	39	60297	2777	63425909
Heart rate abnormal	63.63	11.75	46	60290	4901	63423785
Clostridium difficile infection	63.28	11.75	107	60229	29815	63398871
Colitis	62.77	11.75	141	60195	48387	63380299
Discomfort	62.59	11.75	41	60295	167333	63261353
Hepatic enzyme increased	62.55	11.75	60	60276	202268	63226418
Swelling	61.94	11.75	104	60232	275274	63153412
Red blood cell count decreased	61.67	11.75	126	60210	40519	63388167
Treatment failure	60.40	11.75	60	60276	198983	63229703
Thrombocytopenia	60.40	11.75	294	60042	150863	63277823
Cytokine release syndrome	58.30	11.75	70	60266	14244	63414442
Pancytopenia	57.78	11.75	213	60123	96720	63331966
Rheumatoid arthritis	56.94	11.75	96	60240	253723	63174963
Lower respiratory tract infection	55.76	11.75	28	60308	132279	63296407
Mobility decreased	55.17	11.75	23	60313	121136	63307550
Small intestinal obstruction	54.86	11.75	77	60259	18260	63410426
Folliculitis	54.55	11.75	3	60333	70314	63358372
Psoriatic arthropathy	53.28	11.75	11	60325	91509	63337177
Lymphadenitis	52.82	11.75	35	60301	3240	63425446
Completed suicide	51.39	11.75	38	60298	145635	63283051
Drug abuse	50.83	11.75	5	60331	72513	63356173
Pain	50.43	11.75	456	59880	740172	62688514
Irritable bowel syndrome	49.89	11.75	9	60327	82403	63346283
Failure to thrive	48.52	11.75	46	60290	7152	63421534
Injection site pain	48.25	11.75	32	60304	129768	63298918
Pneumonia	44.88	11.75	645	59691	456122	62972564
Musculoskeletal stiffness	44.05	11.75	67	60269	184551	63244135
Coma	43.67	11.75	5	60331	64359	63364327
General physical health deterioration	43.49	11.75	78	60258	201324	63227362
Paradoxical drug reaction	43.18	11.75	34	60302	4118	63424568
Hair colour changes	42.34	11.75	30	60306	3097	63425589
Fibromyalgia	42.24	11.75	12	60324	80408	63348278
Hypersensitivity	42.20	11.75	140	60196	292545	63136141
Palmar-plantar erythrodysaesthesia syndrome	41.81	11.75	77	60259	22938	63405748
Injection site erythema	40.85	11.75	14	60322	83160	63345526
Sepsis	40.70	11.75	267	60069	152856	63275830
Blood potassium decreased	40.41	11.75	109	60227	41917	63386769
Maternal exposure during pregnancy	40.07	11.75	94	60242	219968	63208718
Weight decreased	39.78	11.75	420	59916	276378	63152308
Pneumonitis	39.71	11.75	97	60239	35125	63393561
Product use issue	38.73	11.75	96	60240	220424	63208262
Abdominal discomfort	38.16	11.75	166	60170	320719	63107967
Anaemia	37.93	11.75	436	59900	292994	63135692
Skin exfoliation	37.71	11.75	108	60228	42994	63385692
Intentional overdose	37.26	11.75	12	60324	74140	63354546
Taste disorder	35.96	11.75	54	60282	13608	63415078
Hypokalaemia	35.93	11.75	194	60142	103610	63325076
Haemoglobin decreased	35.85	11.75	249	60087	145236	63283450
Liver injury	35.79	11.75	7	60329	60513	63368173
Back pain	35.26	11.75	395	59941	263750	63164936
Knee arthroplasty	34.87	11.75	5	60331	54201	63374485
Alopecia areata	34.65	11.75	21	60315	1664	63427022
Blood creatine increased	34.38	11.75	34	60302	5567	63423119
C-reactive protein increased	34.32	11.75	24	60312	94683	63334003
Hair texture abnormal	34.24	11.75	30	60306	4213	63424473
Injection site reaction	34.13	11.75	7	60329	58517	63370169
Weight increased	33.43	11.75	131	60205	260661	63168025
Ill-defined disorder	33.40	11.75	18	60318	81737	63346949
Hyponatraemia	33.38	11.75	201	60135	111699	63316987
Mucosal inflammation	33.04	11.75	109	60227	46819	63381867
Neurologic neglect syndrome	32.06	11.75	24	60312	2697	63425989
Hip arthroplasty	31.59	11.75	4	60332	47642	63381044
Carotid artery thrombosis	31.50	11.75	24	60312	2770	63425916
Rectal cancer metastatic	31.17	11.75	11	60325	245	63428441
Gastric disorder	31.11	11.75	92	60244	37277	63391409
Hypophagia	30.99	11.75	82	60254	31177	63397509
Red blood cell sedimentation rate increased	30.91	11.75	3	60333	43979	63384707
Arthralgia	30.81	11.75	370	59966	569340	62859346
Oral pain	30.74	11.75	77	60259	28317	63400369
Lymphadenopathy	30.43	11.75	93	60243	38365	63390321
Suicide attempt	30.35	11.75	10	60326	60908	63367778
Pyrexia	30.05	11.75	620	59716	469858	62958828
Loss of personal independence in daily activities	29.87	11.75	29	60307	97261	63331425
Blood cholesterol increased	28.90	11.75	28	60308	94004	63334682
Red cell distribution width increased	28.28	11.75	42	60294	10482	63418204
Impaired healing	27.68	11.75	34	60302	102508	63326178
Hypoxia	27.32	11.75	121	60215	59671	63369015
Off label use	27.31	11.75	464	59872	673998	62754688
Overdose	27.21	11.75	42	60294	115036	63313650
Laboratory test abnormal	27.09	11.75	71	60265	26841	63401845
Dysphagia	26.34	11.75	159	60177	88426	63340260
Alopecia	25.47	11.75	202	60134	337334	63091352
Extrapyramidal disorder	24.83	11.75	45	60291	13239	63415447
Type 2 diabetes mellitus	23.38	11.75	16	60320	63852	63364834
Dysgeusia	23.24	11.75	97	60239	46613	63382073
Eating disorder	23.19	11.75	54	60282	18962	63409724
Bacteraemia	23.09	11.75	51	60285	17297	63411389
Deep vein thrombosis	22.78	11.75	147	60189	83653	63345033
Mental status changes	22.73	11.75	86	60250	39513	63389173
Exposure during pregnancy	22.66	11.75	74	60262	155473	63273213
Intentional product misuse	22.65	11.75	15	60321	60902	63367784
Prescribed overdose	22.32	11.75	3	60333	34150	63394536
Dry skin	22.23	11.75	110	60226	56777	63371909
Muscle twitching	21.99	11.75	54	60282	19614	63409072
Cholestasis of pregnancy	21.98	11.75	14	60322	1211	63427475
Injection site swelling	21.69	11.75	9	60327	47563	63381123
Streptococcal bacteraemia	21.67	11.75	16	60320	1761	63426925
Breast cancer metastatic	21.56	11.75	40	60296	11978	63416708
Anuria	21.56	11.75	41	60295	12510	63416176
Haematocrit decreased	21.40	11.75	84	60252	39256	63389430
Cataract	21.36	11.75	109	60227	56944	63371742
Pulmonary embolism	21.14	11.75	186	60150	116498	63312188
Enteritis	20.75	11.75	32	60304	8254	63420432
Therapeutic response decreased	20.48	11.75	17	60319	61508	63367178
Inflammation	20.45	11.75	29	60307	82244	63346442
Sneezing	20.35	11.75	50	60286	18168	63410518
Lymphocyte count decreased	20.17	11.75	69	60267	30188	63398498
Tumour marker increased	19.96	11.75	24	60312	4891	63423795
Skin haemorrhage	19.90	11.75	35	60301	10059	63418627
Chills	19.65	11.75	179	60157	113199	63315487
Madarosis	19.46	11.75	19	60317	3062	63425624
Autoimmune nephritis	19.40	11.75	9	60327	413	63428273
Blood pressure fluctuation	19.21	11.75	10	60326	46307	63382379
Embolism	19.05	11.75	30	60306	7876	63420810
Systemic inflammatory response syndrome	18.93	11.75	25	60311	5596	63423090
Pregnancy	18.43	11.75	6	60330	36830	63391856
Skull fracture	18.38	11.75	12	60324	1083	63427603
Asthma	18.36	11.75	61	60275	127500	63301186
Personality disorder	18.28	11.75	25	60311	5786	63422900
Angina pectoris	17.83	11.75	66	60270	30012	63398674
Neutropenic colitis	17.55	11.75	18	60318	3077	63425609
Clostridium difficile colitis	17.46	11.75	51	60285	20518	63408168
Injection site bruising	17.45	11.75	9	60327	41901	63386785
Nasopharyngitis	17.43	11.75	156	60180	254101	63174585
Drug hypersensitivity	17.41	11.75	402	59934	310285	63118401
Adjustment disorder	17.15	11.75	18	60318	3160	63425526
Palpitations	17.05	11.75	173	60163	112597	63316089
Plasma cell myeloma recurrent	16.99	11.75	18	60318	3195	63425491
Bacterial translocation	16.97	11.75	7	60329	241	63428445
Acquired cystic kidney disease	16.96	11.75	5	60331	61	63428625
Urinary tract infection	16.91	11.75	349	59987	264335	63164351
Medication error	16.73	11.75	15	60321	52269	63376417
Joint range of motion decreased	16.73	11.75	5	60331	32423	63396263
Ovarian cancer recurrent	16.72	11.75	11	60325	1006	63427680
Coronary artery disease	16.69	11.75	5	60331	32372	63396314
Tremor neonatal	16.66	11.75	6	60330	142	63428544
Oesophagitis	16.56	11.75	41	60295	14967	63413719
Drug interaction	16.41	11.75	139	60197	228992	63199694
Injury	16.12	11.75	28	60308	73219	63355467
Morbid thoughts	16.09	11.75	9	60327	614	63428072
Aphasia	16	11.75	68	60268	32932	63395754
Motor dysfunction	15.89	11.75	33	60303	10728	63417958
Sensory loss	15.83	11.75	32	60304	10206	63418480
Injection site pruritus	15.60	11.75	12	60324	45104	63383582
Oculogyric crisis	15.59	11.75	13	60323	1708	63426978
Osteoarthritis	15.58	11.75	43	60293	95300	63333386
Sleep disorder	15.51	11.75	34	60302	81532	63347154
Multiple sclerosis relapse	15.40	11.75	14	60322	48464	63380222
Sedation	15.19	11.75	9	60327	38800	63389886
Intentional self-injury	15.13	11.75	3	60333	25684	63403002
Tremor	15.08	11.75	192	60144	132047	63296639
Pancreatic carcinoma recurrent	15.06	11.75	5	60331	92	63428594
Acute myeloid leukaemia	15.03	11.75	43	60293	17104	63411582
Dyssomnia	14.87	11.75	4	60332	34	63428652
Blood pressure systolic increased	14.69	11.75	14	60322	47383	63381303
Ascites	14.68	11.75	77	60259	40651	63388035
Hypermagnesaemia	14.61	11.75	10	60326	976	63427710
Pulmonary fibrosis	14.53	11.75	10	60326	39799	63388887
Blister	14.30	11.75	69	60267	129745	63298941
Hemiplegia	14.25	11.75	29	60307	9294	63419392
Parkinsonism	14.25	11.75	31	60305	10408	63418278
Abdominal infection	14.08	11.75	13	60323	1955	63426731
Hepatotoxicity	13.93	11.75	9	60327	37032	63391654
Serotonin syndrome	13.83	11.75	59	60277	28623	63400063
Klebsiella bacteraemia	13.81	11.75	12	60324	1666	63427020
Oesophageal ulcer	13.65	11.75	19	60317	4471	63424215
Depressed level of consciousness	13.42	11.75	24	60312	62054	63366632
Breast cellulitis	13.39	11.75	8	60328	618	63428068
Dizziness	13.36	11.75	517	59819	429408	62999278
Lymph node pain	13.31	11.75	11	60325	1427	63427259
Blood bilirubin increased	13.24	11.75	70	60266	37070	63391616
Hepatitis	13.24	11.75	11	60325	39777	63388909
Neutropenic sepsis	13.24	11.75	40	60296	16398	63412288
Liver iron concentration abnormal	12.93	11.75	4	60332	58	63428628
Pubic pain	12.93	11.75	5	60331	145	63428541
Plasmacytoma	12.85	11.75	14	60322	2565	63426121
Incorrect route of product administration	12.83	11.75	5	60331	27447	63401239
Dyspepsia	12.79	11.75	151	60185	102045	63326641
Lethargy	12.70	11.75	94	60242	55913	63372773
Blood sodium decreased	12.56	11.75	51	60285	24201	63404485
Osteoporosis	12.55	11.75	22	60314	57316	63371370
Immune effector cell-associated neurotoxicity syndrome	12.47	11.75	13	60323	2264	63426422
Metastases to liver	12.47	11.75	50	60286	23589	63405097
Heart rate decreased	12.40	11.75	15	60321	45545	63383141
Non-small cell lung cancer	12.12	11.75	16	60320	3579	63425107
Vulvovaginal injury	12.08	11.75	7	60329	511	63428175
Sciatica	12.04	11.75	9	60327	34315	63394371
Bone pain	11.99	11.75	91	60245	54550	63374136
Stress	11.96	11.75	29	60307	67138	63361548
Enterocolitis infectious	11.95	11.75	11	60325	1647	63427039
Lipase increased	11.95	11.75	28	60308	9872	63418814
Pica	11.79	11.75	3	60333	20	63428666

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	579.79	12.65	723	36852	136126	34783230
Fatigue	218.89	12.65	880	36695	369773	34549583
Plasma cell myeloma	194.84	12.65	233	37342	41804	34877552
Dehydration	145.79	12.65	385	37190	129584	34789772
Nausea	142.43	12.65	730	36845	339178	34580178
Death	135.51	12.65	808	36767	397241	34522115
Disease progression	117.93	12.65	317	37258	107760	34811596
Malignant neoplasm progression	117.73	12.65	279	37296	87767	34831589
Diarrhoea	114.23	12.65	762	36813	389150	34530206
Pneumonia	102.71	12.65	703	36872	361924	34557432
Decreased appetite	99.85	12.65	398	37177	165994	34753362
Vomiting	94.60	12.65	519	37056	247102	34672254
Drug ineffective	88.24	12.65	229	37346	456522	34462834
Drug abuse	86.36	12.65	5	37570	99091	34820265
White blood cell count decreased	81.00	12.65	256	37319	95189	34824167
Drug interaction	72.18	12.65	82	37493	225864	34693492
Condition aggravated	70.25	12.65	62	37513	192134	34727222
Toxicity to various agents	69.27	12.65	68	37507	200294	34719062
Neuropathy peripheral	66.69	12.65	219	37356	83044	34836312
Constipation	62.51	12.65	302	37273	136680	34782676
Hospice care	62.37	12.65	55	37520	6885	34912471
Cytokine release syndrome	59.41	12.65	96	37479	22781	34896575
Platelet count decreased	58.30	12.65	269	37306	119448	34799908
Full blood count decreased	56.96	12.65	83	37492	18005	34901351
Neutropenia	50.22	12.65	314	37261	156464	34762892
Completed suicide	49.12	12.65	22	37553	98146	34821210
Meconium abnormal	47.06	12.65	12	37563	70	34919286
Failure to thrive	45.36	12.65	51	37524	8550	34910806
Neutrophil count decreased	45.07	12.65	139	37436	50965	34868391
Bacteraemia	43.57	12.65	77	37498	19640	34899716
Small intestinal obstruction	42.21	12.65	65	37510	14801	34904555
Overdose	41.64	12.65	23	37552	91036	34828320
Rash	40.50	12.65	391	37184	222361	34696995
Therapeutic product effect incomplete	37.43	12.65	5	37570	50536	34868820
Product use in unapproved indication	37.06	12.65	43	37532	117456	34801900
Back pain	34.73	12.65	237	37338	121552	34797804
Neoplasm progression	34.56	12.65	77	37498	23223	34896133
Necrotising enterocolitis neonatal	33.91	12.65	12	37563	237	34919119
Sepsis	33.06	12.65	298	37277	166263	34753093
Asthenia	32.79	12.65	405	37170	244846	34674510
Intentional overdose	30.77	12.65	5	37570	43669	34875687
Deep vein thrombosis	30.53	12.65	145	37430	65103	34854253
Intentional product misuse	30.45	12.65	6	37569	45605	34873751
Muscle spasms	29.69	12.65	159	37416	74842	34844514
Coma	28.49	12.65	7	37568	45671	34873685
Bradycardia	26.70	12.65	25	37550	75393	34843963
Suicide attempt	26.42	12.65	5	37570	39111	34880245
Rhabdomyolysis	26.06	12.65	21	37554	68142	34851214
Pulmonary embolism	25.78	12.65	175	37400	89571	34829785
General physical health deterioration	25.61	12.65	63	37512	128206	34791150
Ageusia	25.06	12.65	42	37533	10266	34909090
Injection site pain	24.28	12.65	6	37569	38999	34880357
Thrombosis	24.23	12.65	113	37462	50345	34869011
Adverse drug reaction	24.20	12.65	78	37497	29264	34890092
Psoriasis	24.10	12.65	6	37569	38806	34880550
Laboratory test abnormal	23.38	12.65	61	37514	20330	34899026
C-reactive protein increased	22.85	12.65	15	37560	54083	34865273
Weight decreased	22.60	12.65	289	37286	176012	34743344
Oral pain	22.28	12.65	41	37534	10786	34908570
Cardiac failure	22.25	12.65	40	37535	91208	34828148
Hypophagia	21.78	12.65	66	37509	23956	34895400
Rheumatoid arthritis	21.73	12.65	7	37568	38231	34881125
Spinal cord compression	21.70	12.65	24	37551	3951	34915405
Enterocolitis infectious	20.59	12.65	16	37559	1679	34917677
Dysgeusia	20.56	12.65	69	37506	26428	34892928
Pleural effusion	20.50	12.65	154	37421	81392	34837964
Clostridium difficile infection	20.11	12.65	55	37520	18843	34900513
Coronary artery disease	19.59	12.65	14	37561	48291	34871065
Immune effector cell-associated neurotoxicity syndrome	19.55	12.65	22	37553	3691	34915665
Haematochezia	19.52	12.65	13	37562	46521	34872835
Hiccups	19.28	12.65	37	37538	10045	34909311
Pancytopenia	19.23	12.65	171	37404	94986	34824370
Fluid imbalance	18.97	12.65	8	37567	257	34919099
Pneumonitis	18.62	12.65	79	37496	33799	34885557
Dystonia	18.57	12.65	38	37537	10807	34908549
Treatment failure	18.34	12.65	14	37561	46683	34872673
Wrong technique in product usage process	18.09	12.65	8	37567	35978	34883378
Laparotomy	17.31	12.65	8	37567	321	34919035
Drug reaction with eosinophilia and systemic symptoms	17.13	12.65	7	37568	33005	34886351
Mental status changes	16.63	12.65	83	37492	38000	34881356
Hyponatraemia	16.39	12.65	148	37427	82543	34836813
Diaphragmatic rupture	16.37	12.65	4	37571	19	34919337
Bacillus bacteraemia	15.99	12.65	5	37570	66	34919290
Temperature intolerance	15.88	12.65	19	37556	3403	34915953
Retching	15.71	12.65	27	37548	6734	34912622
Urinary tract infection pseudomonal	15.65	12.65	11	37564	990	34918366
Therapeutic response decreased	15.57	12.65	6	37569	29307	34890049
Therapeutic product effect decreased	15.55	12.65	9	37566	34734	34884622
Oesophagitis	15.54	12.65	40	37535	13221	34906135
Inappropriate schedule of product administration	15.46	12.65	27	37548	62269	34857087
Mixed dementia	15.38	12.65	7	37568	271	34919085
Cholestasis	15.19	12.65	5	37570	26943	34892413
Blood potassium decreased	15.11	12.65	48	37527	17867	34901489
Inferior vena caval occlusion	15.06	12.65	4	37571	28	34919328
Cardiogenic shock	14.90	12.65	5	37570	26613	34892743
Eosinophilia	14.55	12.65	5	37570	26217	34893139
Drug dependence	14.55	12.65	4	37571	24213	34895143
Hypoxia	14.38	12.65	105	37470	54990	34864366
Streptococcal bacteraemia	14.30	12.65	14	37561	2001	34917355
Stomatitis	14.10	12.65	86	37489	42428	34876928
Blood pressure fluctuation	13.69	12.65	5	37570	25244	34894112
Wrist deformity	13.49	12.65	7	37568	362	34918994
Anaemia	13.46	12.65	337	37238	232998	34686358
Plasma cell myeloma recurrent	13.35	12.65	20	37555	4445	34914911
Hair colour changes	13.24	12.65	13	37562	1864	34917492
Red blood cell count decreased	13.12	12.65	64	37511	29026	34890330
Asthma	13.02	12.65	16	37559	42640	34876716
Toothache	12.90	12.65	24	37551	6364	34912992
Cancer pain	12.67	12.65	15	37560	2657	34916699

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	1173.46	11.39	1286	77454	229713	79435935
Dehydration	356.08	11.39	768	77972	247419	79418229
Disease progression	324.30	11.39	621	78119	183741	79481907
Plasma cell myeloma	289.43	11.39	308	78432	52951	79612697
Drug ineffective	277.59	11.39	400	78340	1080513	78585135
Nausea	275.51	11.39	1747	76993	955449	78710199
Diarrhoea	271.48	11.39	1636	77104	878853	78786795
Fatigue	267.57	11.39	1697	77043	928030	78737618
White blood cell count decreased	254.33	11.39	569	78171	187719	79477929
Vomiting	247.77	11.39	1302	77438	664526	79001122
Malignant neoplasm progression	185.79	11.39	413	78327	135577	79530071
Platelet count decreased	176.62	11.39	506	78234	194158	79471490
Death	173.40	11.39	1052	77688	565462	79100186
Toxicity to various agents	151.32	11.39	117	78623	421423	79244225
Contraindicated product administered	140.86	11.39	3	78737	157535	79508113
Decreased appetite	137.53	11.39	685	78055	341733	79323915
Neutropenia	137.09	11.39	605	78135	287105	79378543
Pneumonia	136.15	11.39	1114	77626	659132	79006516
Synovitis	134.26	11.39	3	78737	150731	79514917
Neutrophil count decreased	131.26	11.39	288	78452	93671	79571977
Constipation	123.51	11.39	580	78160	282470	79383178
Drug abuse	123.02	11.39	10	78730	162681	79502967
Cytokine release syndrome	117.85	11.39	161	78579	35837	79629811
Arthropathy	113.86	11.39	19	78721	177092	79488556
Neoplasm progression	112.25	11.39	191	78549	51491	79614157
Condition aggravated	111.49	11.39	203	78537	500921	79164727
Hospice care	109.77	11.39	87	78653	10237	79655411
Therapeutic product effect decreased	104.40	11.39	18	78722	163845	79501803
Asthenia	102.94	11.39	859	77881	510830	79154818
Completed suicide	100.45	11.39	59	78681	245708	79419940
Therapeutic product effect incomplete	98.50	11.39	12	78728	141633	79524015
Failure to thrive	97.32	11.39	86	78654	11758	79653890
Small intestinal obstruction	92.35	11.39	124	78616	27148	79638500
Sepsis	90.29	11.39	513	78227	268915	79396733
Joint swelling	85.87	11.39	95	78645	288551	79377097
Systemic lupus erythematosus	84.88	11.39	10	78730	121139	79544509
Blood magnesium decreased	81.81	11.39	91	78649	16421	79649227
Neovascularisation	80.11	11.39	34	78706	1211	79664437
Pleural effusion	79.61	11.39	319	78421	144943	79520705
Clostridium difficile infection	78.86	11.39	147	78593	42538	79623110
Full blood count decreased	77.49	11.39	113	78627	26706	79638942
Thrombosis	72.68	11.39	215	78525	83885	79581763
Abdominal pain	70.90	11.39	640	78100	388929	79276719
Colitis	70.73	11.39	195	78545	73112	79592536
Drug intolerance	69.03	11.39	96	78644	264023	79401625
Coma	68.82	11.39	9	78731	100640	79565008
Neuropathy peripheral	68.58	11.39	299	78441	141006	79524642
Pancytopenia	65.27	11.39	330	78410	165415	79500233
Bacteraemia	64.37	11.39	116	78624	32708	79632940
Drug interaction	62.46	11.39	206	78534	414977	79250671
Intentional overdose	60.54	11.39	15	78725	105945	79559703
Akathisia	60.47	11.39	70	78670	13189	79652459
Injection site pain	59.21	11.39	27	78713	129811	79535837
Gangrene	58.03	11.39	57	78683	8907	79656741
Overdose	57.69	11.39	58	78682	184148	79481500
Arterial occlusive disease	57.05	11.39	55	78685	8401	79657247
Thrombocytopenia	56.24	11.39	451	78289	264808	79400840
Heart rate abnormal	55.89	11.39	47	78693	6010	79659638
Off label use	55.89	11.39	600	78140	906615	78759033
General physical health deterioration	55.48	11.39	118	78622	275120	79390528
Pericarditis	53.58	11.39	18	78722	104218	79561430
Hair colour changes	52.30	11.39	39	78701	4193	79661455
Pneumonitis	52.02	11.39	155	78585	60705	79604943
Carbohydrate antigen 125 increased	51.14	11.39	30	78710	2154	79663494
Red blood cell count decreased	50.61	11.39	148	78592	57365	79608283
C-reactive protein increased	49.88	11.39	33	78707	128994	79536654
Hyponatraemia	48.37	11.39	321	78419	177527	79488121
Glossodynia	47.88	11.39	21	78719	103316	79562332
Suicide attempt	46.87	11.39	12	78728	82920	79582728
Psoriatic arthropathy	46.63	11.39	10	78730	77989	79587659
Back pain	46.55	11.39	482	78258	303698	79361950
Discomfort	46.08	11.39	34	78706	125583	79540065
Hypophagia	46.07	11.39	123	78617	45244	79620404
Intentional product misuse	44.63	11.39	19	78721	95146	79570502
Palmar-plantar erythrodysaesthesia syndrome	44.47	11.39	100	78640	33034	79632614
Pulmonary embolism	44.39	11.39	306	78434	171348	79494300
Musculoskeletal stiffness	43.35	11.39	66	78674	174942	79490706
Folliculitis	42.99	11.39	3	78737	55377	79610271
Lower respiratory tract infection	42.42	11.39	39	78701	129181	79536467
Oral pain	41.60	11.39	95	78645	31703	79633945
Rheumatoid arthritis	41.47	11.39	90	78650	208380	79457268
Hepatic enzyme increased	41.38	11.39	73	78667	182537	79483111
Deep vein thrombosis	40.93	11.39	231	78509	120688	79544960
Lymphadenitis	40.66	11.39	35	78705	4620	79661028
Hypoxia	40.22	11.39	205	78535	103038	79562610
Anaemia	39.20	11.39	637	78103	444378	79221270
Mental status changes	39.05	11.39	150	78590	66809	79598839
Wound	38.21	11.39	35	78705	116144	79549504
Hypersensitivity	38.10	11.39	132	78608	262107	79403541
Treatment failure	37.86	11.39	69	78671	170417	79495231
Mobility decreased	37.64	11.39	39	78701	122136	79543512
Weight decreased	37.30	11.39	524	78216	354674	79310974
Pyrexia	37.09	11.39	904	77836	677805	78987843
Weight increased	36.78	11.39	145	78595	277241	79388407
Swelling	36.49	11.39	102	78638	216609	79449039
Blood potassium decreased	35.60	11.39	114	78626	46398	79619250
Blood pressure fluctuation	35.56	11.39	11	78729	67134	79598514
Enterocolitis infectious	34.47	11.39	26	78714	2843	79662805
Red blood cell sedimentation rate increased	34.23	11.39	3	78737	45939	79619709
Infusion related reaction	34.05	11.39	115	78625	230122	79435526
Immune effector cell-associated neurotoxicity syndrome	33.85	11.39	35	78705	5813	79659835
Taste disorder	33.71	11.39	58	78682	15765	79649883
Haemoglobin decreased	33.49	11.39	351	78389	221768	79443880
Dysgeusia	33.26	11.39	128	78612	57049	79608599
Injection site erythema	33.02	11.39	18	78722	78179	79587469
Injection site reaction	32.80	11.39	7	78733	54778	79610870
Asthma	32.45	11.39	52	78688	135043	79530605
Oesophagitis	32.26	11.39	73	78667	24216	79641432
Alopecia areata	32.18	11.39	21	78719	1822	79663826
Knee arthroplasty	31.75	11.39	3	78737	43245	79622403
Mucosal inflammation	31.51	11.39	153	78587	75427	79590221
Loss of personal independence in daily activities	31.31	11.39	33	78707	102547	79563101
Streptococcal bacteraemia	31.26	11.39	27	78713	3579	79662069
Coronary artery disease	30.81	11.39	13	78727	65461	79600187
Rectal cancer metastatic	30.63	11.39	13	78727	463	79665185
Dysphagia	29.96	11.39	215	78525	121921	79543727
Fibromyalgia	29.92	11.39	13	78727	64327	79601321
Hair texture abnormal	29.71	11.39	26	78714	3508	79662140
Product use in unapproved indication	29.42	11.39	137	78603	250222	79415426
Nasopharyngitis	29.21	11.39	140	78600	253741	79411907
Enteritis	29.18	11.39	52	78688	14531	79651117
Inflammation	28.79	11.39	30	78710	93723	79571925
Liver injury	28.70	11.39	10	78730	56604	79609044
Dry skin	28.60	11.39	138	78602	67857	79597791
Rhabdomyolysis	28.43	11.39	36	78704	103095	79562553
Pain	28.30	11.39	507	78233	703295	78962353
Drug reaction with eosinophilia and systemic symptoms	28.30	11.39	14	78726	64230	79601418
Neurologic neglect syndrome	27.74	11.39	23	78717	2884	79662764
Medication error	27.28	11.39	17	78723	68625	79597023
Irritable bowel syndrome	26.76	11.39	14	78726	62227	79603421
Carotid artery thrombosis	26.75	11.39	23	78717	3030	79662618
Eosinophilia	26.72	11.39	6	78734	45339	79620309
Paradoxical drug reaction	26.38	11.39	34	78706	7151	79658497
Blood pressure systolic increased	26.06	11.39	17	78723	66969	79598679
Systemic inflammatory response syndrome	25.71	11.39	43	78697	11422	79654226
Embolism	25.63	11.39	48	78692	13934	79651714
Red cell distribution width increased	25.09	11.39	50	78690	15192	79650456
Sedation	24.91	11.39	10	78730	51885	79613763
Arthralgia	24.88	11.39	406	78334	571397	79094251
Therapeutic response decreased	24.64	11.39	18	78722	66835	79598813
Injection site swelling	24.46	11.39	8	78732	47124	79618524
Gastric disorder	24.45	11.39	87	78653	37346	79628302
Hypokalaemia	24.29	11.39	233	78507	143807	79521841
Bradycardia	24.17	11.39	62	78678	135495	79530153
Ill-defined disorder	23.94	11.39	18	78722	65857	79599791
Lymphocyte count decreased	23.64	11.39	101	78639	47188	79618460
Product use issue	23.38	11.39	117	78623	209705	79455943
Hepatitis	23.28	11.39	13	78727	55714	79609934
Klebsiella bacteraemia	23.04	11.39	21	78719	2989	79662659
Cancer pain	22.77	11.39	27	78713	5218	79660430
Impaired healing	22.73	11.39	32	78708	87623	79578025
Skin exfoliation	22.58	11.39	111	78629	54989	79610659
Depressed level of consciousness	22.46	11.39	38	78702	96614	79569034
Heart rate decreased	22.16	11.39	22	78718	70294	79595354
Ageusia	22.10	11.39	50	78690	16582	79649066
Cholestasis of pregnancy	21.58	11.39	13	78727	980	79664668
Injury	21.41	11.39	27	78713	77469	79588179
Haematocrit decreased	21.31	11.39	118	78622	61194	79604454
Cardiac failure	21.11	11.39	80	78660	154762	79510886
Performance status decreased	21.00	11.39	28	78712	6085	79659563
Cytomegalovirus infection	20.83	11.39	8	78732	42636	79623012
Bacterial translocation	20.71	11.39	11	78729	651	79664997
Stress	20.71	11.39	29	78711	79583	79586065
Retching	20.47	11.39	50	78690	17417	79648231
Madarosis	20.38	11.39	19	78721	2783	79662865
Blood cholesterol increased	20.31	11.39	32	78708	83688	79581960
Non-small cell lung cancer	20.14	11.39	28	78712	6332	79659316
Intentional self-injury	19.70	11.39	4	78736	32415	79633233
Blood creatine increased	19.29	11.39	34	78706	9421	79656227
Cholestasis	19.24	11.39	14	78726	52095	79613553
Metastatic renal cell carcinoma	19.15	11.39	17	78723	2338	79663310
Myelosuppression	18.96	11.39	8	78732	40288	79625360
Eating disorder	18.91	11.39	54	78686	20643	79645005
Hypermagnesaemia	18.90	11.39	13	78727	1231	79664417
Hip arthroplasty	18.68	11.39	6	78734	35750	79629898
Cardiogenic shock	18.66	11.39	9	78731	41905	79623743
Clostridium difficile colitis	18.55	11.39	72	78668	32211	79633437
Inappropriate schedule of product administration	18.24	11.39	69	78671	133559	79532089
Wrong technique in product usage process	18.15	11.39	28	78712	73847	79591801
Osteoporosis	18.15	11.39	16	78724	54096	79611552
Abdominal infection	17.97	11.39	20	78720	3609	79662039
Oculogyric crisis	17.69	11.39	18	78722	2934	79662714
Cholangitis	17.64	11.39	39	78701	12737	79652911
Blood sodium decreased	17.38	11.39	72	78668	33183	79632465
Prescribed overdose	17.07	11.39	8	78732	37875	79627773
Obstructive airways disorder	16.93	11.39	5	78735	31454	79634194
Tumour marker increased	16.93	11.39	21	78719	4251	79661397
Lymphadenopathy	16.88	11.39	100	78640	53147	79612501
Dystonia	16.88	11.39	53	78687	21346	79644302
Joint range of motion decreased	16.66	11.39	6	78734	33276	79632372
Injection site bruising	16.51	11.39	10	78730	40992	79624656
Obesity	16.49	11.39	7	78733	35118	79630530
Transposition of the great vessels	16.48	11.39	5	78735	65	79665583
Drug dependence	16.34	11.39	10	78730	40759	79624889
Aphasia	16.28	11.39	90	78650	46642	79619006
Acute myeloid leukaemia	16.24	11.39	67	78673	30818	79634830
Acquired cystic kidney disease	16.20	11.39	5	78735	69	79665579
Atrial fibrillation	16.18	11.39	280	78460	197606	79468042
Chorioretinitis	16.11	11.39	11	78729	1029	79664619
Pulmonary fibrosis	16.09	11.39	12	78728	44100	79621548
Spinal cord compression	15.77	11.39	25	78715	6352	79659296
Muscle twitching	15.70	11.39	57	78683	24707	79640941
Haematochezia	15.69	11.39	40	78700	87605	79578043
Type 2 diabetes mellitus	15.68	11.39	20	78720	57102	79608546
Mixed dementia	15.64	11.39	7	78733	284	79665364
Urticaria	15.50	11.39	113	78627	185088	79480560
Agranulocytosis	15.48	11.39	13	78727	45017	79620631
Diabetes mellitus	15.44	11.39	34	78706	78356	79587292
Chills	15.44	11.39	233	78507	160001	79505647
Dizziness	15.43	11.39	651	78089	525790	79139858
Hypophosphataemia	15.41	11.39	49	78691	19864	79645784
Bone pain	15.37	11.39	101	78639	55641	79610007
Metastases to liver	15.35	11.39	62	78678	28252	79637396
Therapy non-responder	15.11	11.39	44	78696	92261	79573387
Sinus tachycardia	14.87	11.39	74	78666	36834	79628814
Hypoglycaemia	14.83	11.39	51	78689	101543	79564105
Inferior vena caval occlusion	14.82	11.39	4	78736	33	79665615
Confusional state	14.81	11.39	415	78325	317582	79348066
Incorrect route of product administration	14.80	11.39	8	78732	34921	79630727
Injection site pruritus	14.79	11.39	12	78728	42271	79623377
Diabetes mellitus inadequate control	14.73	11.39	3	78737	24261	79641387
Urinary tract infection	14.73	11.39	365	78375	274147	79391501
Colon cancer metastatic	14.36	11.39	14	78726	2167	79663481
Autoimmune nephritis	14.34	11.39	9	78731	730	79664918
Fluid imbalance	14.26	11.39	8	78732	528	79665120
Lymph node pain	14.24	11.39	12	78728	1538	79664110
Muscle spasms	14.19	11.39	247	78493	174483	79491165
Anaphylactic shock	14.19	11.39	9	78731	35987	79629661
Multiple sclerosis relapse	14.16	11.39	15	78725	46518	79619130
Hyperglycaemia	14.02	11.39	118	78622	70217	79595431
Escherichia bacteraemia	13.91	11.39	24	78716	6538	79659110
Breast cancer metastatic	13.90	11.39	28	78712	8574	79657074
Renal cell carcinoma	13.87	11.39	24	78716	6554	79659094
Foetal heart rate abnormal	13.79	11.39	7	78733	377	79665271
Pneumothorax	13.77	11.39	60	78680	28263	79637385
Skin haemorrhage	13.73	11.39	34	78706	11947	79653701
Personality disorder	13.72	11.39	23	78717	6123	79659525
Drug eruption	13.55	11.39	14	78726	43921	79621727
Sciatica	13.52	11.39	8	78732	33214	79632434
Adjustment disorder	13.25	11.39	18	78722	3982	79661666
Oxygen saturation decreased	13.23	11.39	74	78666	128973	79536675
Pregnancy	13.18	11.39	5	78735	26846	79638802
Blood bilirubin increased	13.14	11.39	111	78629	66121	79599527
Oral candidiasis	13.09	11.39	61	78679	29567	79636081
Maternal exposure during pregnancy	13.09	11.39	80	78660	136458	79529190
Respiratory arrest	13.03	11.39	23	78717	57527	79608121
Psychotic disorder	12.99	11.39	13	78727	41389	79624259
Oesophageal ulcer	12.85	11.39	24	78716	6951	79658697
Skull fracture	12.81	11.39	12	78728	1768	79663880
Mean cell haemoglobin concentration decreased	12.80	11.39	19	78721	4560	79661088
Liver iron concentration abnormal	12.78	11.39	4	78736	58	79665590
Fear	12.77	11.39	3	78737	21983	79643665
Hypogeusia	12.73	11.39	12	78728	1782	79663866
Urinary tract infection pseudomonal	12.71	11.39	12	78728	1786	79663862
Grip strength decreased	12.67	11.39	3	78737	21866	79643782
Bacillus bacteraemia	12.65	11.39	5	78735	148	79665500
Pancreatic carcinoma metastatic	12.60	11.39	17	78723	3736	79661912
Feeding disorder	12.58	11.39	40	78700	16214	79649434
Sleep disorder	12.51	11.39	43	78697	85634	79580014
Malignant pleural effusion	12.42	11.39	16	78724	3364	79662284
Arthritis infective	12.28	11.39	26	78714	8245	79657403
Labelled drug-drug interaction medication error	12.21	11.39	6	78734	27644	79638004
Exposure during pregnancy	12.07	11.39	55	78685	101077	79564571
Erythema	11.98	11.39	152	78588	223138	79442510
Sensory loss	11.97	11.39	34	78706	12957	79652691
Tremor	11.92	11.39	235	78505	169848	79495800
Muscular weakness	11.92	11.39	224	78516	160505	79505143
Lung squamous cell carcinoma metastatic	11.88	11.39	4	78736	74	79665574
Hypoalbuminaemia	11.83	11.39	47	78693	21250	79644398
Palpitations	11.77	11.39	183	78557	126427	79539221
Stomatitis	11.75	11.39	207	78533	146550	79519098
Blood alkaline phosphatase increased	11.74	11.39	105	78635	63559	79602089
Pancreatic carcinoma recurrent	11.68	11.39	5	78735	182	79665466
Lymphatic disorder	11.64	11.39	6	78734	334	79665314
Pubic pain	11.63	11.39	5	78735	184	79665464
Myocardial infarction	11.57	11.39	121	78619	184008	79481640
Epilepsy	11.53	11.39	14	78726	40846	79624802
Hypovolaemia	11.45	11.39	41	78699	17650	79647998

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AB04	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperazine structure
FDA CS	M0016525	Phenothiazines
MeSH PA	D000932	Antiemetics
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:48873	acetylcholine receptor antagonist
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:65190	typical antipsychotic drugs
CHEBI has role	CHEBI:76779	post-proline endopeptidase inhibitors
CHEBI has role	CHEBI:131787	D2R antagonist
FDA EPC	N0000175746	Phenothiazine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Schizophrenia	indication	58214004	DOID:5419
Nonpsychotic Anxiety	indication
Prolonged-Severe Nausea and Vomiting	indication
Migraine	off-label use	37796009	DOID:6364
Chemotherapy-induced nausea and vomiting	off-label use	236084000
Brain damage	contraindication	2470005
Tachyarrhythmia	contraindication	6285003
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Severe chronic ulcerative colitis	contraindication	14311001
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Toxic megacolon	contraindication	28536002	DOID:1770
Orthostatic hypotension	contraindication	28651003
Atony of colon	contraindication	29479008
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Conduction disorder of the heart	contraindication	44808001
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Ulcerative colitis	contraindication	64766004	DOID:8577
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Extrapyramidal disease	contraindication	76349003
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Hyperglycemia	contraindication	80394007	DOID:4195
Hiatal hernia	contraindication	84089009	DOID:12642
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Gastrointestinal obstruction	contraindication	126765001
Acute disease of cardiovascular system	contraindication	128487001
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Angina pectoris	contraindication	194828000
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Drowsy	contraindication	271782001
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Visual impairment	contraindication	397540003
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Gastrointestinal disturbances associated with emotional stress	Indication
Dogs	Gastrointestinal disturbances associated with emotional stress	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Darbazine Spansule Capsule No.1	Zoetis Inc.	2
Darbazine Injectable	Zoetis Inc.	2
Neo-Darbazine Spansule Capsule No.1, Neo-Darbazine Spansule Capsule No.3	Zoetis Inc.	3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.74	Basic
pKa2	4.74	Basic
pKa3	2.21	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.76	WOMBAT-PK	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	ANTAGONIST	Ki	8.61	WOMBAT-PK	IUPHAR
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	7.20	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.64	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.82	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.21	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.40	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.23	PDSP
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.82	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.19	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.91	WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.91	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7.62	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	8.32	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	7.72	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.61	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.96	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.49	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.72	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.80	DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.92	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.86	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	6.52	DRUG MATRIX
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	7.17	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.89	DRUG MATRIX
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		IC50	5.70	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.25	DRUG MATRIX
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.30	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	7.11	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.31	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	5.92	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.38	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	7.49	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	6.02	CHEMBL
5-hydroxytryptamine receptor 4	GPCR		5HT4R_CAVPO		Ki	6.71	DRUG MATRIX
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	5.77	CHEMBL

External reference:

ID	Source
4018001	VUID
N0000146346	NUI
D00479	KEGG_DRUG
84-02-6	SECONDARY_CAS_RN
1257-78-9	SECONDARY_CAS_RN
4017999	VANDF
4018000	VANDF
4018001	VANDF
C0033229	UMLSCUI
CHEBI:8435	CHEBI
CHEMBL728	ChEMBL_ID
DB00433	DRUGBANK_ID
CHEMBL1200587	ChEMBL_ID
CHEMBL1314751	ChEMBL_ID
CHEMBL1201154	ChEMBL_ID
D011346	MESH_DESCRIPTOR_UI
4917	PUBCHEM_CID
7279	IUPHAR_LIGAND_ID
699	INN_ID
YHP6YLT61T	UNII
235739	RXNORM
2073	MMSL
5361	MMSL
5362	MMSL
5363	MMSL
6416	MMSL
6417	MMSL
d00355	MMSL
001478	NDDF
001479	NDDF
001480	NDDF
003466	NDDF
22827004	SNOMEDCT_US
372853006	SNOMEDCT_US
3823007	SNOMEDCT_US
395843006	SNOMEDCT_US
79129001	SNOMEDCT_US
P77	PDB_CHEM_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5105	TABLET, FILM COATED	5 mg	ORAL	ANDA	14 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5110	TABLET, FILM COATED	10 mg	ORAL	ANDA	14 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	0440-8190	TABLET	5 mg	ORAL	ANDA	12 sections
Compro	HUMAN PRESCRIPTION DRUG LABEL	1	0574-7226	SUPPOSITORY	25 mg	RECTAL	ANDA	19 sections
Compro	HUMAN PRESCRIPTION DRUG LABEL	1	0574-7226	SUPPOSITORY	25 mg	RECTAL	ANDA	19 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6135	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6135	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6225	INJECTION	5 mg	INTRAMUSCULAR	ANDA	17 sections
Prochlorperazine	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0135	SUPPOSITORY	25 mg	RECTAL	ANDA	13 sections
Prochlorperazine	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0135	SUPPOSITORY	25 mg	RECTAL	ANDA	13 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0351	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0351	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5020	TABLET, FILM COATED	5 mg	ORAL	ANDA	18 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5021	TABLET, FILM COATED	10 mg	ORAL	ANDA	18 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-281	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-511	TABLET	5 mg	ORAL	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	14789-700	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
PROCHLORPERAZINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-327	TABLET	10 mg	ORAL	ANDA	10 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-571	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-572	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-294	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-497	INJECTION	5 mg	INTRAMUSCULAR	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-523	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	25021-790	INJECTION	5 mg	INTRAVENOUS	ANDA	18 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	25021-790	INJECTION	5 mg	INTRAVENOUS	ANDA	18 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-141	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-550	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-728	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-729	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	42708-103	TABLET	10 mg	ORAL	ANDA	12 sections